CPD-002 is an inhibitor of vascular endothelial growth factor receptor 2 (VEGFR 2), which inhibits angiogenesis by inhibiting the VEGFR2/PI3K/AKT signaling pathway. CPD-002 has anti-inflammatory activity and can alleviate rheumatoid arthritis.

Physicochemical Properties

Molecular Formula	C17H16N4O2S
Molecular Weight	340.40
CAS #	2617376-08-4
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	CPD-002 (0-64 μM, 24-48 h) is cytotoxic to HUVEC and MH7A cells in a dose-dependent manner [1]. CPD-002 (0-8 μM, 24 h) inhibits VEGF-induced HUVEC cell migration and invasion by suppressing F-actin expression and chemotactic response to chemoattractants released by MH7A cells [1]. CPD-002 (0-8 μM) exerts anti-inflammatory activity by inhibiting inflammatory mediators such as TNF-α, IL-1β, IL-6, IL-8, MMP2, and MMP9, thereby inhibiting synovial angiogenesis[1]. CPD-002 (0-8 μM, 9 days) inhibits HUVEC tube formation and aortic ring sprout formation in an isolated rat aortic ring assay [1].
ln Vivo	CPD-002 (15-60 mg/kg, intraperitoneally, once daily for 14 days) exhibits anti-arthritic and anti-angiogenic activities in an adjuvant-induced arthritis rat model [1].
Cell Assay	Cell Viability Assay[1] Cell Types: HUVECs and MH7A Tested Tested Concentrations: 0-64 μM Incubation Duration: 24-48 h Experimental Results: Inhibited cell viability in a dose-dependent manner. Cell Migration Assay [1] Cell Types: HUVECs Tested Tested Concentrations: 0-8 μM Incubation Duration: 24 h Experimental Results: Inhibited HUVECs migration in a dose-dependent manner.
Animal Protocol	Animal/Disease Models: adjuvant-induced arthritis (AIA) Sprague Dawley rats models[1] Doses: 15-60 mg/kg Route of Administration: i.p., once daily for 14 days Experimental Results: Ameliorated paw swelling, joint damage, and synovial angiogenesis.
References	[1]. CPD-002, a novel VEGFR2 inhibitor, relieves rheumatoid arthritis by reducing angiogenesis through the suppression of the VEGFR2/PI3K/AKT signaling pathway. Int Immunopharmacol. 2024 Apr 20;131:111850.

Solubility Data

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.9377 mL	14.6886 mL	29.3772 mL
	5 mM	0.5875 mL	2.9377 mL	5.8754 mL
	10 mM	0.2938 mL	1.4689 mL	2.9377 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.